Drug Trial Radar · NCT01332968
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Last checked: Nov 19, 2026Latest source record: Aug 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,401
Actual
Start
Jul 6, 2011
Primary completion
Feb 1, 2016
Study completion Jul 30, 2021
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- German Low Grade Lymphoma Study Group; Institute of Cancer Research, United Kingdom
- First posted
- Apr 11, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response \[CR\] or partial response \[PR\]) will undergo a maintenance period continuing on the randomized antibody treatment alone every 2 months until disease progression for a total of 2 years. Anticipated time on study treatment is up to approximately 2.5 years. After maintenance or observation, participants will be followed for 5 years until progression. After progression, participants will be followed for new anti-lymphoma therapy and overall survival until the end of the study.
Conditions
- Non-Hodgkin's Lymphoma
Interventions
ObinutuzumabDrug
Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
CyclophosphamideDrug
Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
DoxorubicinDrug
Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
VincristineDrug
Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
PrednisoneDrug
Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
BendamustineDrug
Bendamustine 90 mg/m\^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
RituximabDrug
Rituximab 375 milligrams per square meter (mg/m\^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m\^2 every 2 months during maintenance period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival in the Follicular Lymphoma Population, Investigator-AssessedTime frame: Baseline up to data cut-off (up to approximately 4 years and 7 months)
Locations
183 sites in 18 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Springdale, Arkansas
The Regents of the University of California; Office of Research
Irvine, California
Kootenai Cancer Center
Post Falls, Idaho
Illinois Cancer Care, P.C. - Galesburg
Galesburg, Illinois
Siouxland Hematology/Oncology
Sioux City, Iowa
University of Kansas; Medical Center & Medical pavilion
Westwood, Kansas
Cancer Center of Kansas
Wichita, Kansas
Mercy Medical Research Institute
Springfield, Missouri
MT Cancer Inst Fndtn; MT Can Spec
Missoula, Montana
San Juan Oncology Associates
Farmington, New Mexico
Providence St. Vincent Medical Center
Portland, Oregon
Northwest Medical Specialties
Tacoma, Washington
Concord Repatriation General Hospital; Haematology
Sydney, New South Wales, Australia
Westmead Hospital; Haematology
Sydney, New South Wales, Australia
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology
Woolloongabba, Queensland, Australia
St Vincent'S Hospital; Haematology
Fitzroy, Victoria, Australia
Peter MacCallum Cancer Centre; Department of Haematology
Melbourne, Victoria, Australia
Austin and Repatriation Medical Centre; Cancer Services
Melbourne, Victoria, Australia
Monash Medical Centre; Haematology
Melbourne, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
UZ Gent
Ghent, Belgium
AZ Groeninge
Kortrijk, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Tom Baker Cancer Centre-Calgary
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Dr. Georges L. Dumont University Hospital Centre
Moncton, New Brunswick, Canada
Ottawa General Hospital
Ottawa, Ontario, Canada
North York General Hospital
Toronto, Ontario, Canada
Humber River Hospital
Toronto, Ontario, Canada
Toronto East General Hospital; Haematology/Oncology
Toronto, Ontario, Canada
Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie
Greenfield Park, Quebec, Canada
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, China
Peking University First Hospital
Beijing, China
Beijing Cancer Hospital
Beijing, China
General Hospital of Chinese PLA; Department of Hematology
Beijing, China
the First Hospital of Jilin University
Changchun, China
Fujian Medical University Union Hospital
Fuzhou, China
Sun Yet-sen University Cancer Center
Guangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Jiangsu Province Hospital
Nanjing, China
Showing 40 of 183 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.